Bio-Path Holdings stock value increased 180% due to positive obesity drug trial results.

From Barchart: 2024-12-29 08:00:02

Bio-Path Holdings saw a 180% increase in stock value after positive results from their obesity drug trials. This shift in focus from cancer treatments to obesity could be a game changer for investors. The company’s success comes after facing challenges with Nasdaq delisting. This news highlights the potential of Bio-Path Holdings to make a significant impact in the medical field.



Read more at Barchart: Is This Penny Stock a Buy After a 180% Rally?